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ABSTRACT 
The four dengue virus serotypes (DENV1-4) are mosquito-borne flaviviruses that infect ~390 
million people annually; up to 100 million infections are symptomatic, and 500,000 cases 
progress to severe disease.  Exposure to a heterologous DENV serotype, the specific infecting 
DENV strains, and the interval of time between infections, as well as age, ethnicity, genetic 
polymorphisms, and co-morbidities of the host, are all risk factors for severe dengue. In contrast, 
neutralizing antibodies (NAbs) are thought to provide long-lived protection against symptomatic 
infection and severe dengue.  The objective of dengue vaccines is to provide balanced protection 
against all DENV serotypes simultaneously.  However, the association between homotypic and 
heterotypic NAb titers and protection against symptomatic infection remains poorly understood.  
Here, we demonstrate that the titer of pre-infection cross-reactive NAbs correlates with reduced 
likelihood of symptomatic secondary infection in a longitudinal pediatric dengue cohort in 
Nicaragua.  The protective effect of NAb titers on infection outcome remained significant when 
controlled for age, number of years between infections, and epidemic force, as well as with 
relaxed or more stringent criteria for defining inapparent DENV infections.  Further, individuals 
with higher NAb titers immediately after primary infection had delayed symptomatic infections 
compared to those with lower titers.  However, overall NAb titers increased modestly in 
magnitude and remained serotype cross-reactive in the years between infections, possibly due to 
re-exposure. These findings establish that anti-DENV NAb titers correlate with reduced 
probability of symptomatic DENV infection and provide novel insights into longitudinal 
characteristics of antibody-mediated immunity to DENV in an endemic setting. 
 
 
SIGNIFICANCE 
The four dengue virus serotypes (DENV1-4) are the most prevalent arboviruses worldwide and 
cause outcomes ranging from inapparent infection to severe disease.  Neutralizing antibodies are 
believed to be critical for protection and therefore for dengue vaccines, but the titers required to 
prevent symptomatic DENV infection have not been well-established.  Here, we show that 
higher pre-infection neutralizing antibody titers correlate with lower probability of symptomatic 
infection in children in a longitudinal cohort study in Nicaragua.  Further, we find evidence that 
levels of cross-reactive neutralizing antibodies are maintained over time, possibly due to re-
exposure.  These findings provide insight into the determinants of DENV infection outcome and 
long-term immunity in an endemic setting and are relevant for dengue vaccine development.   
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INTRODUCTION  
Dengue virus (DENV) is a mosquito-borne flavivirus that infects up to 390 million individuals 
each year (1).  While most infections are inapparent, ~25% of infections cause acute febrile 
illness, which progresses to severe disease in half a million individuals annually (2). DENV 
consists of four evolutionarily distinct, antigenically related DENV serotypes, DENV1-4, and 
neutralizing antibodies (NAbs) against the four serotypes are considered a critical component of 
the protective immune response (3, 4).  Primary (1°) DENV infection induces a NAb response 
that is described as increasingly type-specific over time, providing long-term protection against 
the 1° infecting serotype but only transient protection against other DENV serotypes (5, 6). 
Cross-serotype protection against symptomatic infection is observed for up to two years after 1° 
infection, after which point individuals are at increased risk of symptomatic infection and severe 
dengue upon subsequent heterologous infection (7–10).  Over time, cross-serotype-reactive 
antibodies are thought to decay to sub-neutralizing levels, binding but not neutralizing DENV 
and contributing to enhanced replication during heterologous infection by facilitating virus entry 
into target cells expressing Fc receptors (11).  However, following subsequent infection with a 
different serotype, the NAb response becomes broadly neutralizing, and is thought to reduce 
incidence of severe disease (12).  
 
There has been limited success in establishing the relationship between the level of pre-infection 
NAb titers to DENV and risk of disease upon subsequent DENV infection in endemic settings.  
In recent vaccine trials, symptomatic disease was observed in individuals with relatively high 
NAb titers, raising concerns that the current immunologic assays do not measure the NAbs 
critical for protection (13).  In studies of infants, who receive IgG antibodies by trans-placental 
transfer from DENV-immune mothers, infants with higher NAb titers at birth generally, although 
not always, experienced symptomatic disease later than those with lower titers (14–16).  Recent 
studies in children and adults have made important advances in demonstrating an association 
between the quantity of cross-reactive pre-infection NAb titers and reduced risk of symptomatic 
secondary (2°) infection, defined as >2 infections, but have not been conclusive: the association 
did not hold for all DENV serotypes (15, 17), exposure could not be proven for DENV-negative 
individuals (18), or the magnitude of pre-infection NAb titers was not directly studied (12, 19).  
Thus, there is an urgent need to definitively establish whether NAb titers correlate with 
protection in endemic settings.  Here, we estimated the relationship between pre-infection NAb 
titers and probability of symptomatic infection and characterized determinants of long-term 
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protection in children with multiple DENV infections in a pediatric dengue cohort study in 
Nicaragua. 
 
RESULTS  
Selection of the repeat infection sample set.  The Nicaraguan Pediatric Dengue Cohort Study 
(PDCS, 2004-present) is a community-based study with “enhanced” passive surveillance with an 
average active cohort of ~3,500 children (7,547 to date) aged 2-14 years in Managua. Healthy 
annual blood samples are collected from all participants each year (in July/August prior to 2011 
and March/April since 2011).  Symptomatic infections are confirmed in children who present to 
the study Health Center with suspected dengue or undifferentiated febrile illnesses by RT-PCR 
and/or virus isolation in acute samples, and/or serological assays in paired acute and 
convalescent samples (20).  Inapparent infections are identified using Inhibition ELISA (IE) on 
paired healthy annual samples processed side-by-side each year, defined as seroconversion (1° 
infections) or a >4-fold increase in anti-DENV antibody titer (2° infections) (21).  By IE, we 
capture ~80% of symptomatic infections, as reported previously (21).   In total, 1,114 children 
were DENV-naïve at enrollment and experienced >1 infection.  From this group, we assembled 
the “repeat infection sample set” by randomly selecting 62/224 with 2 infections and 32/54 with 
3 infections as identified by either IE or symptomatic infection; 18/834 with 1 infection were 
also selected for comparison (n=112 total) (9).  Children in the sample set were an average of 
6.19 years old at the time of their first DENV infection, and 45% were female (see SI Appendix, 
Table S1). 
 
To reconstruct the immunological history of each child in the repeat infection sample set, NAb 
titers to the four DENV serotypes were measured in annual samples from all available years.  
NAb titers were measured by endpoint titration and calculated as 50% neutralization (NT50) in a 
flow cytometry-based assay using human Raji-DC-SIGNR cells with reporter virus particles 
(RVPs) representing the four DENV serotypes (9, 22).  Titrations were only accepted once they 
met stringent quality control standards (see Methods) (9).   
 
Inapparent infections were classified using the same criteria as previously reported (9): a >4-fold 
increase in NAb titer between annual samples to a DENV serotype other than a previous 
infecting DENV serotype or a serotype that later caused a symptomatic infection (hereafter 
called the standard infection criteria).  Based on analyses of reproducibility of positive control 
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titrations, we expect identical serum samples titrated against all four DENV types at two time-
points to exhibit a >4-fold increase in titer for at least one of the four measured titers, and thus 
incorrectly be coded as an infection, in only 0.9-1.0% of comparisons (see SI Appendix, Fig. 
S1). Compared with inapparent infections identified by applying standard infection criteria to the 
NAb titers, inapparent infections identified by IE had a specificity 95% and a sensitivity of 64%. 
With standard infection criteria, we identified 22 symptomatic 1°, 71 inapparent 1°, 38 
symptomatic 2°, and 87 inapparent 2° DENV infections.  Based on NAb responses, the children 
were grouped into the following subsets: subset 1 entered the study DENV-naïve and had >2 
infections (n=69); subset 2 entered the study DENV-immune and >1 infection (n=19); and subset 
3 entered the study DENV-naïve and had only 1 infection (n=24) (see SI Appendix, Table S2).  
 
We also identified the infecting serotype as described in Methods. The serotype identified by 
RT-PCR corresponded to the greatest change in NAb titers in 94% of symptomatic 2° infections,!and!41% exhibited original antigenic sin, defined as a post-infection NAb titer higher to the 1° 
than to the 2° infecting serotype.  For inapparent 2° infections, we identified the infecting 
serotype by considering the magnitude of the change in NAb titer as well as the epidemiology of 
DENV in the year of infection, as others have done (10), based on DENV infection data for the 
full PDCS (21).  With these criteria, 76% of infections had the largest change in NAb titer to 
what was identified as the 2° infecting serotype, and 60% exhibited original antigenic sin. 
 
Pre-infection neutralizing antibody titer predicts infection outcome.  We first tested whether 
higher levels of cross-reactive NAb titers reduced the probability of symptomatic infection by 
estimating the relationship between pre-infection NAb titers measured in the annual sample 
before the 2° infection and symptomatic versus inapparent 2° DENV infections for subset 1, 
using single and multiple logistic regression.  Pre-infection NAb titers were estimated as the 
median of NAb titers to the four serotypes, and covariates included age at 2° infection, number 
of years between 1° and 2° infection, or “epidemic force”, a metric based on the annual ratio of 
symptomatic to inapparent (S:I) infections in the full PDCS (See Methods and SI Appendix, Fig. 
S2). 
 
In all multiple logistic regression models, children with a higher median pre-infection NAb titer 
were significantly less likely to experience symptomatic 2° infections (Fig. 1A, Table 1; see SI 
Appendix, Tables S3, S4).  When covariates in all models were set to the average value observed 
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in the sample, the probability of symptomatic infection decreased with higher levels of pre-
infection median NAb titer (Fig. 1B). Based on the model “median NAb titer + epidemic force”, 
individuals with a titer of 1:260 have a 10% probability of symptomatic infection in an average 
year. We tested the predictive ability of the model “median NAb titer + epidemic force” with 
cross-validation (see Methods).! Overall, the predicted probabilities corresponded well to the 
observed proportions of symptomatic DENV infections for each estimated probability group, 
similar to model parameters estimated with all children in subset 1 (see SI Appendix, Table S5). 
We expanded our analyses of protection to also include subset 2 (DENV-immune upon study 
enrollment) and found that the protective effect of median pre-infection NAb titer remained 
significant (see SI Appendix, Table S6). In contrast, the pre-infection NAb titer to the 1° 
infecting serotype was not significantly associated with infection outcome, suggesting that the 
heterotypic NAbs were providing protection (Table 1; see SI Appendix, Tables S3-S4, S6). 
 
Alternative criteria for identifying inapparent DENV infections do not change the 
relationship between median pre-infection NAb titer and infection outcome.  We conducted 
sensitivity analyses to determine whether the protective effect of median pre-infection NAb titer 
was robust to the criteria used to identify inapparent infections.  Using “relaxed” infection 
criteria, defined as any >4-fold increase in NAb titer, thus allowing for re-infection with previous 
infecting serotypes, those in subset 1 with a higher median pre-infection NAb titer were at 
reduced risk of symptomatic disease (Table 1; see SI Appendix, Tables S2-S4).  The relationship 
remained when also analyzing subsets 2 and 3 with the “relaxed” infection criteria (see SI 
Appendix, Table S6). We then applied more stringent criteria for inapparent infections, which 
consisted of the standard criteria as well as a median NAb titer increase of >1-fold.  Although 
this reduced the number of inapparent infections, the effect of median pre-infection NAb titer on 
infection outcome remained (Table 1; see SI Appendix, Tables S3-S4, S6). We concluded that 
potential misclassification of inapparent infections would not substantively alter the measured 
relationship between NAb titer and protection.  
 
Pre-infection neutralizing antibody titer to the 2° infecting serotype predicts infection 
outcome.  We next tested whether the pre-infection NAb titer to the 2° infecting serotype was 
predictive of infection outcome.  We found that, controlling for epidemic force or years between 
1° and 2° infections, the NAb titer to the 2° infecting serotype was also associated with reduced 
likelihood of symptomatic infection (Table 1; see SI Appendix, Tables S3-S4, S6, Fig. S3A-C).   
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The effect size for the model “NAb titer to 2° serotype + epidemic force” remained similar when 
relaxed and stringent infection criteria were used (Table 1; see SI Appendix, S3-S4, S6), and also 
performed well in cross-validation analyses (Table S5). 
 
Epidemic force is the strongest independent predictor of symptomatic infection.  We found 
that infection during years with a strong epidemic force, at older age, and with more time 
between 1° and 2° infection were all significantly associated with a higher probability of 
symptomatic 2° infection (Table 1).  However, the logistic model with “NAb titer + epidemic 
force” was more parsimonious (Akaike Information Criterion, AIC=102.2) than those with either 
age (AIC=117.0) or years between infections (AIC=116.5), and only epidemic force remained a 
significant independent predictor of symptomatic disease when controlling for age and years 
between 1° and 2° infections in the same regression model (See Methods and SI Appendix, 
Table S7).  DENV serotypes, genotypes, and strains differ their capacity to cause 
symptomatic/severe disease as well as large epidemics (23, 24).  The 2009-2010 epidemic 
season, when DENV3 genotype III was circulating in Nicaragua (21, 25), had a strong epidemic 
force and thus a large independent risk of symptomatic disease (see SI Appendix, Fig. S2).  
When each model covariate was set to the value observed in 2009-2010, the effect of NAb titer 
on the probability of symptomatic infection was more striking (Fig. 1C) than that observed for 
average covariate values (Fig. 1B). 
  
Primary infection outcome modifies 2° infection outcome. We also tested whether the 
infecting DENV serotype and clinical outcome of the 1° infection modified the probability of 
symptomatic 2° infection in the model, “NAb titer + epidemic force”.  Children with 
symptomatic 1° infections were less likely to have symptomatic 2° infections independent of 
NAb titer (median or 2° serotype), suggesting that symptomatic 1° infection may modify 
subsequent disease risk in a way not fully measured by NAb titers.  In contrast, we did not 
observe a significant relationship between either the 1° serotype or the 2° serotype and 
symptomatic 2° infection (see SI Appendix, Table S8).  
 
Higher titers immediately after 1° infection delay the occurrence of symptomatic infection.  
In studies of symptomatic dengue in infants of DENV-immune mothers, infants with later 
symptomatic infections have higher NAb titers at birth than those infected earlier (14–16), 
suggesting that infants exposed after maternal antibodies had decayed to low levels were at 
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greater risk.  We tested this hypothesis for subset 1 to determine whether children with higher 
NAb titers to the 2° infecting serotype immediately after 1° infection were protected for a longer 
period of time against symptomatic infection. We found that every two-fold higher NAb titer to 
the 2° serotype, as measured immediately after 1° infection, provided a six-month delay to 
symptomatic infection (Fig. 2A).  We hypothesized that NAb titers would decay to low levels in 
all individuals in the year prior to their symptomatic 2° infections.  However, we did not observe 
a significant difference in NAb titers to the 2° infecting serotype from immediately after 1° 
infection to the year before 2° symptomatic infection (paired t-test, 1.23-fold increase, p=0.21) 
and children with later 2° infections, both symptomatic and inapparent, had more >4-fold 
increases in NAb titers between their 1° and 2° infections than those with earlier 2° infections 
(p<0.001, linear regression).  Yet overall, those with 2° inapparent infections still consistently 
had higher pre-infection NAb titers than those with 2° symptomatic infections (Fig. 2B; see SI 
Appendix, Fig. S3D). These observations suggest that the increase in NAb titers may have been 
due to intermediate DENV exposures.  
 
Neutralizing antibody titers increase in magnitude and breadth following 1° infection.  In 
the absence of re-infection with DENV, post-1° infection NAb responses are expected to decay 
and become increasingly type-specific over time (5).  We measured the magnitude and breadth 
of NAb titer trajectories following 1° infection and before the subsequent exposure to DENV (as 
identified with standard criteria) for subset 1 (>2 infections) and subset 3 (1 infection) (see 
Methods).  In both subsets 1 and 3, we observed that the magnitude of NAb titers between 1° and 
subsequent infection increased modestly, but significantly (Fig. 3; see SI Appendix, Table S9). A 
similar phenomenon was seen for the breadth of the NAb response: those in subset 1 became 
slightly more cross-serotype neutralizing over time, while subset 3 had stable NAb responses.  In 
subset 1, we also measured the trajectories of NAb titers between 2° infections defined with 
standard criteria.  NAb titers modestly declined in magnitude, but had stable cross-serotype 
neutralization over time (Fig. 3; see SI Appendix, Table S9).  
 
DISCUSSION 
We have found that pre-infection NAb titers reduce the risk of symptomatic DENV infection in a 
longitudinal dengue cohort.  We observed that a higher median pre-infection NAb titer or NAb 
titer to the 2° infecting serotype, but not the NAb titer to the 1° serotype, was significantly 
associated with reduced probability of 2° symptomatic DENV infection, indicating that cross-
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reactive NAbs determine protection, as others have proposed (7, 8, 12, 17, 19).  The protective 
effect of pre-infection NAb titers remained when the criteria for inapparent infections were 
relaxed or made more stringent, and the models performed well in cross-validation experiments, 
reinforcing the strength of this observation.  We also found that higher NAb titers to the 2° 
infecting type immediately after 1° infection delayed symptomatic 2° infections, but that this 
effect could not be attributed primarily to antibody decay, as NAb titers increased modestly in 
magnitude and remained serotype cross-reactive in the years between 1° and 2° infection.  
Collectively, our findings establish that higher levels of cross-reactive pre-infection NAb titers 
correlate with reduced probability of symptomatic DENV infection, and that NAb titers do not 
become increasingly type-specific over time in endemic settings. 
  
Our findings advance those of previous studies to establish the relationship between the quantity 
of NAbs and protection against DENV in an endemic setting.  Previous longitudinal cohort 
studies in Thailand found that pre-infection NAb titers reduce the risk of severe disease (17), 
while studies in Sri Lanka and Peru found that the number of DENV serotypes that were 
detectably neutralized reduced the risk of symptomatic compared with inapparent 2° DENV 
infection (12, 19). A recent index-cluster study in Thailand found that individuals with 
symptomatic infections had lower pre-infection NAb titers than a comparable group of 
individuals likely, but not definitely, exposed to DENV but who did not become ill (18). 
However, due to study limitations, these findings collectively do not provide definitive proof of 
the relationship between NAb titers and protection: the protective effect was not consistently 
observed against all DENV serotypes (17), the DENV-negative individuals may not have been 
exposed to DENV (18), and the magnitude of NAb titers was not directly analyzed (12, 19).  
Beyond dengue cohort studies, there remains concern that NAb titers measured with non-human 
cell substrates are not as biologically relevant (13). Our study fills a critical gap in the literature, 
establishing that higher levels of pre-infection NAb titers reduce the risk of symptomatic 
compared with inapparent DENV infection in a longitudinal cohort of children infected 
repeatedly over multiple years, as measured using a statistically robust neutralization assay on a 
human cell substrate.  Future studies that measure other functional properties of NAbs will be 
important for establishing the mechanism of such neutralization.  
 
We observed that age, interval between 1° and 2° infections, and epidemic force in the year of 2° 
infection were independent predictors of 2° infection outcome.  However, in models including 
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epidemic force and either age or years between 1° and 2° infections, only epidemic force 
remained significant, suggesting that it was the major independent predictor of infection outcome 
besides pre-infection NAb titer.  Previous studies have found that the time between 1° and 2° 
infections is a strong predictor of infection outcome (7–9).  However, in other studies, age and 
years between infections were used as an indirect measure of NAb titers (older children are more 
likely to have higher NAb titers, and more years between infection may correlate with antibody 
decay), whereas we have estimated the effect of NAb titer on infection outcome directly. 
Interestingly, Anderson et al. (7) observed an effect of time on infection outcome independent of 
antibody response, suggesting that perhaps an effect of epidemic force has been observed in 
other settings.  
 
Epidemic force is likely a function of whether a major epidemic occurred recently, the 
virulence/transmissibility of the infecting serotype and strain, and the antigenic properties of the 
strain in relation to population immunity and the serotypes and strains that circulated previously.  
That there are major fluctuations in the annual S:I ratio is well established and has been observed 
by all longitudinal cohort studies conducted to date (26). The DENV serotypes are also observed 
to have intrinsic differences: DENV1 and DENV3 cause more symptomatic/severe primary 
infections than DENV2 and DENV4, DENV2 causes the most symptomatic/severe secondary 
infections, DENV3 is associated with the largest epidemics, and DENV4 infections tend to be 
mild or subclinical (23, 24, 27, 28).  Within serotypes, there may also be differences in epidemic 
potential of genotypes or clades, due to either their antigenic properties in relation to population 
immunity or their intrinsic fitness differences (28–31). Of note, the years with the strongest 
epidemic force described here coincided with the re-introduction of DENV3 into Nicaragua, 
similar to what occurred in Iquitos, Peru, in 2001-2002, where DENV3 was introduced into a 
population previously only infected with DENV1 and DENV2, leading to an initial high S:I 
infection ratio (24).  Our findings suggest that the NAb titer that distinguishes those with a high 
probability of symptomatic compared with inapparent infection may depend on the annual S:I 
ratio and thus may vary in relation to the risk of disease given DENV infection from year to year 
(29–31).  This raises the possibility that there may not be a single NAb titer that correlates with 
protection from symptomatic infection, even for each DENV serotype, and that it may differ 
from epidemic to epidemic. 
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We also found that the 1° infection outcome independently predicted subsequent symptomatic 
DENV infection.  We did not observe any significant differences in 2° infection outcome by 1° 
or 2° infecting serotype, but our study was not powered to test the specific relationship between 
serotypes. The sequence of infecting serotypes has been shown to be important in other cohorts 
and settings (29, 30).  In future studies using higher resolution antigenic and epidemiological 
data, it may be possible to identify the specific antigenic relationship between the 1° and 2° 
infecting DENV isolates, particularly if using Nicaraguan strains, rather than prototype isolates, 
for the neutralization assays (32). 
 
Our findings also provide insight into the maintenance of protective NAbs in endemic settings. 
We found that children with higher NAb titers immediately after 1° infection were protected for 
longer against symptomatic infection than those with lower titers, but this effect does not appear 
to be due to antibody decay, as NAb titers modestly increased between the year after 1° infection 
and the year before 2° infection.  Our study was conducted in an endemic setting, whereas 
previous studies of neutralizing responses in individuals long after 1° infection were conducted 
in non-endemic areas (5).  However, in a comparable hospital-based study following pediatric 
dengue cases in Nicaragua, NAb titers declined in magnitude between 2 weeks and 6 months 
post-infection, but increased between 6 to 18 months post-infection for a subset of individuals, 
suggesting subsequent DENV-exposure (33). These observations raise the possibility that many 
children in the Nicaraguan cohort were exposed to DENV more often than is measured using 
standard infection criteria.  
 
The frequency of boosts in NAb titer observed in the repeat infection sample set suggest that 
some may have been caused by re-infection with the 1° DENV serotype.  This is consistent with 
the epidemiology of DENV in Nicaragua, where one DENV type generally dominates for 
multiple years at a time.  Currently, only heterologous DENV infections are thought to cause 
infection, as the dogma is that individuals have sterilizing immunity to all variants of the 1° 
infecting serotype (34). However, recent experimental studies in non-human primates 
demonstrate that inoculation with either the same or different genotypes of DENV2 one year 
after 1° DENV2 inoculation can cause a persistent boost in NAb titers as measured by PRNT50, 
particularly if individuals had low NAb titers prior to the DENV2 challenge (35).  Our findings 
suggest that DENV re-exposure may be important for maintaining long-term humoral immunity 
in endemic settings; individuals may have sufficient antibodies to quickly control infection, but 
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experience sufficient replication to stimulate the immune memory cell population and potentially 
increase the quantity of circulating NAbs.  Nagao and Koelle observed in modeling studies that a 
decline in DENV transmission was associated with increased incidence of severe disease, and 
posited that frequent exposure to DENV may be required to maintain sufficient levels of NAbs 
for sustained protection against disease (36).   
 
There are a few considerations for the interpretation of our findings.  The repeat infection sample 
set is only a subset of the Nicaraguan cohort and thus the effect sizes of parameters estimated 
here may differ if studied in the larger cohort.  Specifically, selection for the repeat infection 
sample set may have led to oversampling of individuals with a high rate of DENV exposure.   
Additionally, the 2007-2008 DENV2 epidemic, which caused a disproportionate number of 
severe 2° cases in the full cohort (29), is mostly absent in the repeat infection sample set because 
only children who were DENV-naïve at enrollment were included.  More generally, our findings 
are bound by the specific epidemiology of dengue in Nicaragua over the time-period studied.  
 
Our findings have potential implications for vaccine development and implementation. Vaccines 
that generate higher levels of NAb titers will potentially reduce the probability of symptomatic 
infection, but the level of NAbs required for protection against symptomatic disease may differ 
from year to year in endemic settings.  Further, a vaccine that induces a sufficiently strong NAb 
response to protect against DENV infection for at least a few years may be successful in endemic 
areas, if indeed frequent re-exposure helps maintain high levels of NAbs. However, the same 
vaccine might be less effective in areas with infrequent outbreaks or in travelers if NAb titers 
indeed wane in non-endemic settings.  
 
Overall, we demonstrate that high NAb titers are associated with reduced probability of 
symptomatic infection in DENV-endemic areas.  Further, our data suggest that regular DENV re-
exposure, including to homologous DENV types, may help maintain these high levels of NAb 
titers over time.  
  
MATERIALS AND METHODS 
Neutralization titrations.  NAb titers were measured as 50% neutralization (relative to no 
antibody control) in a flow cytometry-based assay using human Raji-DC-SIGNR cells with 
reporter virus particles (RVPs) representing the four DENV serotypes: DENV1, Western Pacific 
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74; DENV2, S16803; DENV3, CH53489; DENV4, TVP360 (9, 22).  Where possible, all annual 
samples for each child were titrated side-by-side.  The raw antibody titration data were fitted 
with a two-parameter (slope and intercept) sigmoidal dose-response curve to estimate the NAb 
titer (NT50). The RVP concentrations were tested to ensure they abided by the law of mass 
action. Quality control standards were implemented for the sigmoidal dose-response regression 
fit, including an absolute sum of squares <0.2 and the coefficient of determination (R2) >0.9 (9).   
 
Identifying the infecting serotype. If an individual had a >4-fold increase to only one serotype, 
that serotype was identified as the infecting serotype.  However, in Nicaragua, generally one 
DENV serotype causes the majority of infections in any given year.  Thus, if the individual also 
had a >1.5-fold increase in NAb titer to a serotype with higher incidence in that year (based on 
incidence data for the full PDCS), the higher-incidence serotype was identified as the infecting 
serotype. We conducted sensitivity analyses and found that the effect sizes and p-values 
estimated with different fold-increases (>1-fold, >2-fold, or >4-fold) were similar to those 
estimated with >1.5-fold increase. 
 
Epidemic force. The epidemic force was estimated as the annual ratio of symptomatic to 
inapparent (S:I) infections in the full PDCS divided by the average of the S:I ratios across all 
years (2004-2014) to provide a relative, independent measure of risk of symptomatic infection in 
Managua, Nicaragua, for each year (see SI Appendix, Fig. S2). As a sensitivity analysis, we also 
defined epidemic force using only the S:I ratio for 1° infections in the whole PDCS and obtained 
similar results (see SI Appendix, Table S4).   
 
Magnitude and breadth. Magnitude was estimated as the mean of NAb titers to all four DENV 
serotypes for each individual at each time point.  Breadth was estimated by identifying the best 
and second-best neutralized DENV serotypes in the year immediately after 1° infection, and 
measuring the ratio of the two NAb titers for each individual at each time point. 
 
Statistical analyses. All statistical analyses were conducted using R version 3.1.3. We used 
logistic regression to test the association between median pre-infection NAb titers or the NAb 
titer to the 2° serotype and 2° infection outcome, controlling for age at 2° infection, years 
between 1° and 2° infection, or epidemic force.  Effects were estimated as the average marginal 
effect (AME, which allows comparison between models (37)), odds ratios (OR), or the 
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probability of symptomatic infection (the OR/(1+OR)). We conducted cross validation of the 
model “NAb titer + epidemic force” by estimating model parameters with data from a randomly 
selected sample of 90% of children in subset 1 and used the resulting model to predict the 
probability of symptomatic infection for the excluded 10%, repeating this process 10,000 times, 
using different random subsets. We used the AIC to compare logistic regression models with 
pre-infection NAb titer and age, years between 1° and 2° infections, or epidemic force.  We built 
logistic regression models with multiple covariates to test the importance of each in relation to 2° 
infection outcome. We estimated the relationship between NAb titers and years until 2° infection 
with linear regression. Fold-changes in magnitude and breath were estimated with linear 
regression, controlling for each individual’s initial NAb responses with individual intercept 
values. Separate models were run for all individuals with at least 2 years, 3 years, etc. of follow-
up. 
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Figure 1. Higher median pre-infection NAb titers are associated with lower probability of 
symptomatic 2° DENV infection. (A) The year of 2° infection (2006-2013) plotted against the 
median pre-infection NAb titer for all children in subset 1, measured the year before 2° DENV 
infection. Local regression (thin lines, span=1) and linear regression (thick lines) are shown. (B 
and C) Logistic regression model predictions of the association between median pre-infection 
NAb titer and the probability of symptomatic infection (%).  The predicted curves are drawn 
with covariate values set to the average value observed for each covariate (B: epidemic 
force=1.14, age=8.42, number of years between 1° and 2° infection=2.67) or the value observed 
in the 2009-2010 season (C: epidemic force=2.06, age=9.78, number of years between 1° and 2° 
infection=3.18). 
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Figure 2. Higher pre-infection NAb titers are associated with delay in 2° symptomatic DENV 
infection. (A) The linear relationship between NAb titer to the 2° infecting serotype, measured 
immediately after 1° infection, and the number of years until symptomatic 2° infection; slope and 
p-value are shown. (B) The number of years between 1° and 2° infection (1-8) is plotted against 
the median pre-infection NAb titer for all children in subset 1, measured in the year before 2° 
infection.  Local regression (thin lines, span=1) and linear regression (thick lines) are shown.   
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Figure 3. Dynamics of the magnitude and breadth of NAb titers after 1° and before subsequent 
infection (A and B), and between 2° infections (C and D), as measured with standard infection 
criteria.  Plots show the number of years since previous infection against the magnitude (A and 
C) or breadth (B and D) of NAb titers. Thick lines showing the fold-change in the magnitude 
(values >1 are increasing) or breadth (values <1 are more cross-reactive) of NAb titers over time 
were estimated with linear regression. Fold-change estimates (see SI Appendix, Table S9) are 
indicated above regression lines, * indicates statistical significance at p<0.05. 
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Supplement to: 
Neutralizing antibody titers against dengue virus correlate with protection from symptomatic 
infection in a longitudinal cohort 
 
 
Leah C. Katzelnick, Magelda Montoya, Lionel Gresh, Angel Balmaseda, Eva Harris 
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Figure S1.  Positive control reproducibility of two polyvalent serum samples against RVPs 
representing DENV1-4. The positive controls titrated in ten independent experiments had 
standard deviations ranging from 0.38-0.78 log2, less than 2-fold deviation. Figures show 10,000 
random comparisons of the log2 titer differences between any two titrations of the same serum 
and virus conducted on different days.  Values above 2 indicate >4-fold increase between time 
points. Left, World Health Organization (WHO) polyvalent reference antisera, Right, 
Nicaraguan Polyvalent Sera (NPS).  The percentage listed in the title indicates the percent of all 
titer comparisons that would include at least one of the four serotypes having a >4-fold increase, 
leading to erroneous identification of an infection. 
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Figure S2. Method of estimating the epidemic force. (Left) Comparison of annual symptomatic 
to inapparent infection ratios (S:I ratio) for 1° infections (blue) or all infections (purple) in the 
full Nicaraguan Pediatric Dengue Cohort Study (PDCS), or 2° infections (grey) in the repeat 
infection sample set. The horizontal line (dotted black) indicates the average S:I ratio considering 
all infections in the whole PDCS over all years. (Right) The epidemic force, which is the annual 
S:I infection ratio for the whole PDCS divided by the average S:I ratio across all years of the 
whole PDCS (dotted pink line).  The horizontal line (dotted black) indicates the average 
epidemic force, equal to 1.  
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Figure S3. Higher pre-infection NAb titers to the 2° serotype are associated with lower 
probability of symptomatic 2° DENV infection. (A) The year of 2° infection (2006-2013) plotted 
against the pre-infection NAb titer to the 2° serotype for all children in subset 1, measured the 
year before 2° DENV infection.  Local regression (thin lines, span=1) and linear regression 
(thick lines) are shown. (B and C) Logistic regression model predictions of the association 
between pre-infection NAb titer to the 2° serotype and the probability of symptomatic infection 
(%).  The predicted curves are drawn with covariate values set to the average value observed for 
each covariate (B: epidemic force=1.14, age=8.42, number of years between 1° and 2° 
infection=2.67) or the value observed in the 2009-2010 season (C: epidemic force=2.06, 
age=9.78, number of years between 1° and 2° infection=3.18). (D) The number of years between 
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1° and 2° infection (1-8) is plotted against the pre-infection NAb titer to the 2° serotype for all 
children in subset 1, measured in the year before 2° infection.  Local regression (thin lines, 
span=1) and linear regression (thick lines) are shown.   
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Table S1. Demographic characteristics and infection information in the repeat infection 
sample set. 
 
 
Subset 11 (n=69) Subset 22 (n=19) Subset 33 (n=24) Full set (n=112) 
  Mean sd Mean sd Mean sd Mean sd 
Age at first infection4 5.99 2.53 4.84 2.12 7.83 2.99 6.19 2.72 
Year of first infection4 2006-07 1.48 2004-05 1.02 2007-08 1.87 2006-07 1.82 
Percent female (%) 46 
 
37 
 
46 
 
45 
  
1Subset 1: children who entered the study DENV-naïve and had >2 infections (n=69). 
2Subset 2: children who entered the study DENV-immune and had >1 infection (n=19). 
3Subset 3: children who entered the study DENV-naïve and had only one infection (n=24). 
4If immune at study enrollment (subset 2), the year of entry into the PDCS is used instead of the year of 1° infection. 
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Table S2.  Number of 2° infections identified using different criteria for inapparent 
infections.   
 
 
 
 
1Symptomatic infections are denoted S, inapparent infections, I.  
2Standard infection criteria: a >4-fold increase to a DENV serotype an individual has not been infected with previously 
and to which they do not have a later symptomatic DENV infection.   
3Relaxed infection criteria: any >4-fold increase in NAb titer.   
4Stringent infection criteria: a >4-fold increase to a DENV serotype an individual has not been infected with previously 
and to which they do not have a later symptomatic DENV infection, plus an overall increase in median NAb titers. 
!
 
  
 
Subset 1 Subset 2 Subset 3 Full set 
Infection criteria S1 I S I S I S I 
Standard2 32 66 6 21 
  
38 87 
Relaxed3 32 77 6 21 
 
4 38 102 
Stringent4 32 49 6 21 
  
38 70 
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Table S3. Relationship between pre-infection NAb titers and likelihood of symptomatic 2° 
infection (subset 1). 
 
 
1The odds ratio (OR) is change in the odds of symptomatic to inapparent infection for each 2-fold increase in NAb 
titer.  
2The average marginal effect (AME) is the average effect of NAb titer on the probability of symptomatic infection. 
  
 
Single logistic regression (subset 1) 
 
NAb titer 
Variable (Definition of infection) OR1 p AME2 p 
Median NAb titer (standard) 0.75 0.03 -0.06 0.05 
Median NAb titer (relaxed) 0.76 0.03 -0.05 0.05 
Median NAb titer (stringent) 0.82 0.18 -0.05 0.20 
     
NAb titer 1° serotype (standard) 0.93 0.50 -0.02 0.50 
     
NAb titer 2° serotype (standard) 0.84 0.16 -0.04 0.18 
NAb titer 2° serotype (relaxed) 0.83 0.13 -0.04 0.15 
NAb titer 2° serotype (stringent) 0.87 0.29 -0.03 0.30 
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Table S4. Relationship between pre-infection NAb titers and likelihood of symptomatic 2° 
infection (subset 1), with epidemic force estimated from 1° infection S:I ratio in the whole 
PDCS. 
 
 
 
 
 
 
 
 
 
 
 
1The odds ratio (OR) is change in the odds of symptomatic to inapparent DENV infection for each 2-fold increase in 
NAb titer or one unit increase in the epidemic force. 
2The average marginal effect (AME) is the average effect of NAb titer or epidemic force on the probability of 
symptomatic infection. 
3Epidemic force is defined here by the 1° infection S:I ratio in the whole PDCS.  The estimate of epidemic force is 
only shown for the model including pre-infection NAb titer with standard infection criteria, but was included in all 
models.   
  
 Multiple logistic regression model (subset 1) 
 
NAb titer + epidemic force 
Variable (Definition of infection) OR1 p AME2 p 
Median NAb titer (standard) 0.69 0.02 -0.06 0.04 
Epidemic force3 (standard) 6.48 <0.001 0.32 0.01 
Median NAb titer (relaxed) 0.68 0.01 -0.06 0.03 
Median NAb titer (stringent) 0.72 0.07 -0.06 0.10 
     
NAb titer 1° serotype (standard) 0.99 0.95 -0.001 0.95 
     
NAb titer 2° serotype (standard) 0.72 0.03 -0.06 0.05 
Epidemic force3 (standard) 7.08 <0.001 0.35 0.01 
NAb titer 2° serotype (relaxed) 0.71 0.02 -0.06 0.04 
NAb titer 2° serotype (stringent) 0.70 0.03 -0.06 0.06 
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Table S5. Cross-validation of the model “NAb titer + epidemic force” to predict the 
probability of symptomatic infection (%) for subset 1. 
 
% S, predicted 0-101 10-20 20-30 30-40 40-50 50-60 60-70 70-100 
Median NAb titers         
% S, full set 5 33 7 23 45 44 100 80 
% S, test set2 13 23 12 20 42 48 97 79 
         
NAb titer 2° serotype         
% S, full set 7 16 25 23 25 83 71 73 
% S, test set 13 21 11 24 34 69 72 68 
 
1Percent of infections that were symptomatic for each predicted probability (0-10%, 10-20% etc.) of symptomatic 
infection (S).   
2Test set: random 10% of individuals per cross-validation trial, 10,000 separate trials. 
 
 !!!!!
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Table S6. Relationship between pre-infection NAb titers and likelihood of symptomatic 2° 
infection for subsets 1, 2, & 3, in model “Nab titer + epidemic force”. 
 
  Subset 1 & 2 Subset 1, 2 & 31 
 NAb titer + epidemic force NAb titer + epidemic force 
Variable (Definition of infection) OR2 p AME3 p OR p AME p 
Median NAb titer (standard) 0.68 0.01 -0.06 0.03 
    
Epidemic force4 (standard) 4.02 <0.001 0.23 <0.01 
    
Median NAb titer (relaxed) 0.67 0.01 -0.06 0.02 0.66 0.01 -0.06 0.02 
Median NAb titer (stringent) 0.73 0.05 -0.06 0.07     
         
NAb titer 1° serotype (standard) 1.00 0.98 0.00 0.98 
    
         
NAb titer 2° serotype (standard) 0.70 0.01 -0.06 0.03     
Epidemic force4 (standard) 3.91 <0.001 0.23 <0.01     
NAb titer 2° serotype (relaxed) 0.69 0.01 -0.06 0.02 0.69 0.01 -0.06 0.02 
NAb titer 2° serotype (stringent) 0.70 0.02 -0.06 0.04     
 
1All the same as subset 1 & 2 except for relaxed criteria. 
2The odds ratio (OR) is change in the odds of symptomatic to inapparent DENV infection for each 2-fold increase in 
NAb titer or one unit increase in the epidemic force. 
3The average marginal effect (AME) is the average effect of NAb titer or epidemic force on the probability of 
symptomatic infection. 
4The estimate of epidemic force is only shown for the model including pre-infection NAb titer with standard infection 
criteria, but was included in all models.   
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Table S7. Relationship between pre-infection NAb titer and likelihood of symptomatic 2° 
infection, controlling for paired combinations of covariates.  
 
Models OR1 p AME2 p 
Median NAb titer (standard) 0.67 0.01 -0.07 0.04 
Epidemic force (standard) 4.10 <0.001 0.23 0.01 
Age (standard) 1.05 0.63 0.01 0.63 
 
    
Median NAb titer (standard) 0.65 0.02 -0.07 0.04 
Epidemic force (standard) 4.12 <0.001 0.23 0.01 
Years 1° to 2° infection (standard) 1.07 0.68 0.01 0.68 
 
    
Median NAb titer (standard) 0.66 0.01 -0.08 0.03 
Years 1° to 2° infection (standard) 1.27 0.15 0.05 0.17 
Age (standard) 1.13 0.21 0.02 0.23 
     
NAb titer 2° serotype (standard) 0.71 0.02 -0.06 0.05 
Epidemic force (standard) 4.32 <0.001 0.25 0.01 
Age (standard) 1.06 0.55 0.01 0.56 
     
NAb titer 2° serotype (standard) 0.72 0.03 -0.06 0.06 
Epidemic force (standard) 4.72 <0.001 0.26 0.01 
Years 1° to 2° infection (standard) 0.99 0.96 0.00 0.96 
     
NAb titer 2° serotype (standard) 0.78 0.08 -0.05 0.11 
Years 1° to 2° infection (standard) 1.13 0.43 0.02 0.44 
Age (standard) 1.17 0.09 0.03 0.12 
 
1The odds ratio (OR) is change in the odds of symptomatic to inapparent DENV infection for each 2-fold increase in 
NAb titer or one unit increase in the covariate value. 
2The average marginal effect (AME) is the average effect of NAb titer or the covariate on the probability of 
symptomatic infection. 
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Table S8. Relationship between pre-infection NAb titer and likelihood of symptomatic 2° 
infection, controlling epidemic force, 1° infection outcome, 1° infecting serotype, or 2° 
infecting serotype. 
Models OR1 p AME2 p 
Median NAb titer (standard) 0.68 0.03 -0.05 0.06 
Epidemic force (standard) 5.68 <0.001 0.24 0.01 
1° infection outcome (standard) 0.05 0.01 -0.33 <0.001 
     
Median NAb titer (standard) 0.57 0.004 -0.08 0.02 
Epidemic force (standard) 5.80 <0.001 0.26 0.01 
1° infecting serotype3 (standard) 0.67 0.49 -0.06 0.49 
     
Median NAb titer (standard) 0.75 0.10 -0.04 0.13 
Epidemic force (standard) 4.56 <0.001 0.22 0.01 
2° infecting serotype (standard, DENV1, OR=1) 
DENV2 2.31 0.34 0.12 0.31 
DENV3 1.90 0.37 0.10 0.37 
DENV4 0.00 0.99 -0.35 <0.001 
     
NAb titer 2° serotype (standard) 0.55 <0.01 -0.08 0.02 
Epidemic force (standard) 9.20 <0.001 0.29 0.01 
1° infection outcome (standard) 0.02 <0.01 -0.38 <0.001 
     
NAb titer 2° serotype (standard) 0.72 0.03 -0.05 0.06 
Epidemic force (standard) 5.19 <0.001 0.27 0.01 
1° infecting serotype3 (standard) 0.70 0.53 -0.06 0.53 
     
NAb titer 2° serotype (standard) 0.61 0.01 -0.07 0.03 
Epidemic force (standard) 6.59 <0.001 0.26 0.01 
2° infecting serotype (standard, DENV1, OR=1) 
DENV2 2.26 0.36 0.11 0.34 
DENV3 2.23 0.29 0.11 0.29 
DENV4 0.00 0.99 -0.37 <0.001 
1The odds ratio (OR) is change in the odds of symptomatic to inapparent DENV infection for each 2-fold increase in 
NAb titer or one unit increase in the covariate value. 
2The average marginal effect (AME) is the average effect of NAb titer or the covariate on the probability of 
symptomatic infection. 
3Effect of 1° DENV2 infection relative to 1° DENV1 infection (OR=1).  There were not enough 1° DENV3 or DENV4 
infections in the sample set for analysis. 
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Table S9. Trajectories of NAb titer magnitude and breadth in the years between DENV 
infections, as measured with standard infection criteria. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1The fold-changes per year in NAb titer magnitude and breadth were estimated with linear regression (slope), 
controlling for each individual’s initial NAb responses by estimating individual intercept values.  Separate models 
were run for all individuals with at least 2 years, 3 years, etc. of follow-up.  
2Magnitude was measured as the mean of NAb titers to the four serotypes.  Fold-changes in NAb titer magnitude <1 
are decaying over time;  >1, increasing in magnitude; =1, stable.   
3Breadth was measured as the ratio of the NAb titer to 1° infecting serotype and the best-neutralized heterologous 
serotype.  Fold-changes in NAb titer breadth <1 are more cross-reactive over time;  >1, more type-specific; =1, 
stable. 
 
   1° to subsequent infection Between 2° infections 
  Subset 1 Subset 3 Subset 1 
Fold-change in the 
magnitude of NAb titers 
per year2 
Years Est1 p Est p Est p 
2 1.27 0.01 1.12 0.20 0.80 <0.01 
3 1.12 0.02 1.14 0.02 0.86 <0.01 
4 1.07 0.08 1.16 <0.001 0.86 <0.001 
5 1.06 0.10 1.08 0.06 0.88 <0.001 
6 1.06 0.06 1.07 0.06 0.88 <0.001 
7 
  
1.07 <0.05 
  
Fold-change in breadth 
of NAb titers per year3 
 
            
2 0.85 0.51 1.23 0.41 1.10 0.49 
3 0.76 0.03 0.93 0.64 0.98 0.75 
4 0.86 0.12 0.90 0.34 0.98 0.81 
5 0.84 0.03 0.90 0.27 1.01 0.82 
6 0.87 0.06 0.94 0.45 1.02 0.69 
7 
  
0.94 0.42 
  
